Efficacy
The primary endpoint was not reached. The change from baseline to 24 months in the fasting C-peptide was not significantly different in the saxagliptin plus vitamin D group (Effects of Saxagliptin and Saxagliptin plus Vitamin D on Secondary Endpoints. In the prespecified analyses stratified by glutamic acid decarboxylase antibody (GADA) levels, we found that the treatment effect was greater for participants with higher GADA levels at baseline (Fig. 